Galapagos NV has decided to opt-in on the co-promotion of filgotinib with collaboration partner Gilead Sciences in eight European countries, pending approval. Galapagos assumes 35% of the co-promotion efforts in Germany, France, Italy, Spain, the UK, the Netherlands, Belgium, and Luxembourg and the companies will share profits and losses in these territories. Outside the co-promotion territories, Galapagos will be eligible to receive royalties on global sales of filgotinib. Filgotinib is c...